Lanean...
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future tri...
Gorde:
| Argitaratua izan da: | Genome Med |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436227/ https://ncbi.nlm.nih.gov/pubmed/30914057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-019-0631-0 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|